CXCR3 Antikörper (AA 1-326)

Produktnummer ABIN7869194

Dieser Kaninchen Polyklonal Antikörper detektiert spezifisch CXCR3 in WB, ELISA und IHC (p). Es zeigt Reaktivität gegenüber Proben von Maus und Ratte.

Kurzübersicht für CXCR3 Antikörper (AA 1-326) (ABIN7869194)

Target: CXCR3 (Chemokine (C-X-C Motif) Receptor 3 (CXCR3))

Reaktivität: Maus, Ratte

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser CXCR3 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), ELISA, Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Produktdetails anti-CXCR3 Antikörper

Bindungsspezifität: AA 1-326

Verwendungszweck: Cxcr3 Antibody

Aufreinigung: Antigen affinity purified

Immunogen: Recombinant mouse protein (amino acids M1-E326) was used as the immunogen for the Cxcr3 antibody.

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: Optimal dilution of the Cxcr3 antibody should be determined by the researcher.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Buffer: 0.5 mg/mL if reconstituted with 0.2 mL sterile DI water

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: After reconstitution, the Cxcr3 antibody can be stored for up to one month at 4oC. For long-term, aliquot and store at -20oC. Avoid repeated freezing and thawing.

Details zu CXCR3

Target: CXCR3 (Chemokine (C-X-C Motif) Receptor 3 (CXCR3))

Andere Bezeichnung: Cxcr3

Hintergrund: Chemokine receptor CXCR3 is a Galphai protein-coupled receptor in the CXC chemokine receptor family. Other names for CXCR3 are G protein-coupled receptor 9 (GPR9) and CD183. It is mapped to Xq13.1. CXCR3 is expressed on malignant B cells from chronic lymphoproliferative disorders, particularly in patients with CLL, and represents a fully functional receptor involved in chemotaxis of malignant B lymphocytes. It is found that in the absence of known etiologic agents, CXCR3 represents a novel target for therapeutic interference early in type 1 diabetes. CXCR3 signaling is associated with MG pathogenesis and proposed that and CXCR3 may serve as novel drug targets to treat MG. CXCR3A and CXCR3B are involved in the chemotactic and vascular effects of CXCL4L1.

UniProt: O88410